Descripción del proyecto
Nuevos métodos de detección de sustancias químicas alteradoras del metabolismo
Las sustancias químicas que alteran el metabolismo (MDC por sus siglas en inglés) son sustancias químicas naturales y artificiales que alteran el metabolismo y, en última instancia, provocan obesidad y diabetes. El proyecto GOLIATH, financiado con fondos europeos, se propone desarrollar un método integrado para analizar y evaluar las MDC. Sus investigadores abordarán las principales dianas celulares de la alteración metabólica y desarrollarán modelos predictivos y ensayos de detección de toxicidad. Combinadas con datos ómicos, estas herramientas ayudarán a conocer los mecanismos endocrinos y los efectos adversos de las MDC en la salud humana. Los métodos de detección de GOLIATH podrían tener aplicación en el ámbito normativo y dar lugar a unas muy deseadas directrices.
Objetivo
GOLIATH addresses the work programme topic ‘SC1-BHC-27-2018: New testing and screening methods to identify endocrine disrupting chemicals (EDCs)’ by focussing on one of the most urgent regulatory needs, namely the lack of methods for testing EDCs that disrupt metabolism – chemicals collectively referred to as ‘metabolism disrupting chemicals’ (MDCs). MDCs are natural and anthropogenic chemicals that have the ability to promote metabolic changes that can ultimately result in obesity, diabetes and/or fatty liver in humans. GOLIATH will generate the world’s first integrated approach to testing and assessment (IATA) specifically tailored to MDCs. With a focus on the main cellular targets of metabolic disruption – hepatocytes, pancreatic endocrine cells, myocytes and adipocytes - GOLIATH will develop new methods and optimise existing methods that span the entire adverse outcome pathway (AOP) spectrum, using in silico predictive modelling and high throughput screening, (pre-)validated ready-to-use in vitro assays and optimised in vivo toxicity testing guidelines. GOLIATH will provide key information on the endocrine mode of action by which MDCs disrupt metabolic pathways and induce adverse effects on human health by incorporating multi-omics technologies, and translating results from in vitro and in vivo assays to adverse metabolic health outcomes in humans at real life exposures. Given the importance of international acceptance of the developed test methods for regulatory use, GOLIATH will link with ongoing initiatives of the OECD for test method (pre-)validation, IATA and AOP development. With a consortium comprised of world-leading experts in endocrinology, molecular biology, toxicology, epidemiology, test method development, validation and chemical regulation, GOLIATH will be pivotal in the development of an internationally harmonised strategy for testing MDCs, and help to reduce the worldwide rise in metabolic disorders that have reached ‘Goliathan’ proportions.
Ámbito científico
Palabras clave
Programa(s)
Tema(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SC1-2018-Single-Stage-RTD
Régimen de financiación
RIA - Research and Innovation actionCoordinador
3584 CS Utrecht
Países Bajos